Influence of Rosuvastatin on Blood Lipids, Inflammatory Factors, Oxidative Stress and Matrix Metalloproteinases in Patients with Chronic Heart Failure

Objective: To investigate the influence of rosuvastatin on the blood lipids, inflammatory factors, oxidative stress and matrix metalloproteinases (MMPs) in patients with chronic heart failure (CHF).Methods: Totally 114 patients with CHF admitted to Yanan Hospital of TCM were collected from December, 2014 to December 2015, and randomly assigned into observation group (n=57) and control group (n=57). The patients in control group were given conventional treatment for CHF, while those in observation group orally took Rosuvastatin Calcium, 20 mg per time, qd.. The course of treatment was 3 months. The changes of cardiac function parameters, blood lipids-related indexes, inflammatory factors, oxidative stress and matrix metalloproteinases (MMPs) were all observed in two groups before and after treatment.Results: After treatment, left ventricular ejection fraction (LVEF) and level of high-density lipoprotein cholesterol (HDL-C) increased notably, while left ventricular end systolic diameter (LVESD), left ventricular end-diastolic dimension (LVEDD) and levels of triglyceride (TG), total cholesterol (TC) as well as low-density lipoprotein cholesterol (LDL-C) decreased obviously in two groups, which changed more significantly in observation group than those in control group (P<0.05 or P<0.01). After treatment, the levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and C-reactive protein (CRP) decreased significantly in observation group, which were lower than those in control group conspicuously (P<0.01). There was no significant change in control group by comparison to the level of each inflammatory factor (P>0.05). The levels of MDA, MMP-2 and MMP-9 were lower, while the level of SOD was evidently higher in observation group than those in control group, and the differences were shown statistically significant (P<0.01).Conclusion: Rosuvastatin is promising in the treatment of CHF. It can not only improve the cardiac function and regulate blood lipids, but also reduce the levels of inflammatory factors, MMP-2 and MMP-9, and relieve oxidative stress